Tiny transporters could deliver treatment to stroke patients
Swarms of nanoparticles which are 15,000 times smaller than a pinhead may be able to deliver vital drugs to the brain, offering new hope to patients in the early stages of a stroke.
The research, carried out at The University of Manchester, shows that tiny vesicles called liposomes, just 100 nanometres in diameter can translocate through the damaged blood brain barrier following stroke.
And that may offer a way to get vital drugs to the lesions to stop further damage.
The brain is the only organ to have its own security system: a tightly packed network of blood vessels and barriers that allow the entry of essential nutrients while blocking other potentially harmful substances.
However, the barrier also blocks lifesaving drugs, rendering it difficult to treat a range of conditions including stroke.
Now the research carried out on mice and published today in the journal ACS Nano, shows that liposomes can potentially transport life-saving drugs across the barrier.
The researchers were able to generate microscopic pictures of the brain tissue using state of the art imaging techniques, showing the nanomaterial is a viable transporter.
Up to now, scientists haven’t yet devised a reliable way to deliver drugs to damaged brain efficiently – one of the last frontiers in medical science.
But now the team show that following a stroke event, liposomes are able to penetrate the brain by being transported across the tightly packed endothelial cells by using pouch-like structures known as caveolae.
That means doctors might one day be able to protect tissue in the acute phases of a stroke, by delivering drugs – still being developed – that can protect brain’s neurons from further injury.
In the days following a stroke, when brain cells – or neurons- have died, the researchers showed that liposomes are also able to penetrate the brain to help promote the repair of neurons.
Liposomes are made from lipids which are long chains of oily or waxy organic molecules found in all living things.
Stuart Allan Professor of Neuroscience from The University of Manchester said: “The discovery that nanomaterials may be able to facilitate the treatment of stroke is exciting: scientists have long been grappling with the difficulties of treating brain injuries and diseases.”
“The brain blood barrier is a major frontier in neurology, so the prospect of being able to cross it may have applications to other conditions as well – though clearly, much more work needs to be done.”
Dr Zahraa Al-Ahmady, Honorary Research Fellow at The University of Manchester and a Senior Lecturer at Nottingham Trent University, said: “Liposomes are a tried and tested method of delivering drugs to the body – and are currently used to treat patients, for example, to target cancer drugs into the tumour at high doses which increase their concentration relative to other parts of the body. “
“They are easy to manufacture and used across the NHS. But our research shows that Liposomes have important implications for neurologists too.”
Professor Kostas Kostarelos, Chair of Nanomedicine at The University of Manchester said: “This discovery is an important milestone on the use of liposomes for yet another debilitating disease, such as stroke. Liposomes have had a tremendous impact on offering treatment options in oncology, vaccination, lung and skin disease since they were first discovered by British haematologist Alec Bangham, FRS in 1965.”
NOTES FOR EDITORS
Dr Zahraa Al-Ahmady and Professors Stuart Allan and Kostas Kostarelos are available for comment.
The paper ‘Selective Liposomal Transport Through Blood Brain Barrier Disruption in Ischaemic Stroke Reveals Two Distinct Therapeutic Opportunities’ is available under embargo
For media enquires contact:
Media Relations Officer
Faculty of Biology, Medicine and Health
University of Manchester